Immuneering Corp Reports Results for Quarter Ended June 30, 2026

What Happened

• On August 5, 2026, Immuneering Corporation (ticker: IMRX) announced its financial results and operational updates for the quarter ended June 30, 2026. The company furnished a press release with the announcement as Exhibit 99.1 to its Form 8-K filed the same day. The Form 8-K reports results of operations and financial condition under Item 2.02.

Key Details

• Filing date: August 5, 2026; reporting period: quarter ended June 30, 2026.
• The announcement was made via a press release furnished as Exhibit 99.1 to the Form 8-K.
• The Form 8-K covers results of operations and financial condition (Item 2.02) and lists exhibits (Item 9.01).
• The filing does not report any executive departures or other material corporate transactions.

Why It Matters

• This filing signals that Immuneering has released its latest quarterly results and operational progress — key information investors use to evaluate earnings, revenue trends, cash position, and near-term pipeline or program milestones.
• Retail investors should read the furnished press release (Exhibit 99.1) and any accompanying financial statements/disclosures to see revenue, net income or loss, cash runway, and management commentary before making investment decisions.